Colchicine as an anti-inflammatory agent improving cancer prognosis: A therapeutic repurposing perspective
- 4 November 2025
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 53 (1) , 152437
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarctionAmerican Heart Journal, 2024
- Colchicine inhibits the proliferation and promotes the apoptosis of papillary thyroid carcinoma cells likely due to the inhibitory effect on HDAC1Biochemical and Biophysical Research Communications, 2023
- Chemokines and the immune response to cancerImmunity, 2021
- Inflammation and Cancer: Triggers, Mechanisms, and ConsequencesImmunity, 2019
- Interleukin-1 and Related Cytokines in the Regulation of Inflammation and ImmunityImmunity, 2019
- The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammationAtherosclerosis, 2018
- Familial Mediterranean Fever and Incidence of CancerArthritis & Rheumatology, 2017
- Nonresolving InflammationCell, 2010
- Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactionsEuropean Journal of Cancer, 2006
- Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venulesInflammation, 1992